Tirzepatide Resolves Dumping Syndrome and Dangerous Blood Sugar Drops After Bariatric Surgery

Tirzepatide 2.5 mg weekly decreased postprandial glucose peaks, increased postprandial glucose nadirs (preventing dangerous hypoglycemia), improved time in range on CGM, and resolved postprandial bloating and diarrhea from dumping syndrome. First reported use of a dual-incretin agonist for either dumping syndrome or postbariatric hypoglycemia.

Single case report of a 46-year-old woman with prediabetes and obesity post-sleeve gastrectomy presenting with dumping syndrome and postbariatric hypoglycemia. Monitored with continuous glucose monitoring (CGM) before and during tirzepatide treatment.

Dumping syndrome and postbariatric hypoglycemia are frustrating complications of bariatric surgery with limited treatment options. GLP-1 agonists alone have shown mixed results for these conditions. Tirzepatide's dual GIP/GLP-1 mechanism may offer superior glucose stabilization and symptom control, potentially providing a new treatment option for these challenging post-surgical conditions.

As bariatric surgery rates increase, so do its complications. Postbariatric hypoglycemia affects up to 10-30% of gastric bypass patients and has limited treatment options. If tirzepatide's dual-agonist mechanism proves consistently effective, it could become a standard treatment for these post-surgical metabolic complications.

Single case report — the lowest level of evidence. Impossible to generalize from one patient. The dose was very low (2.5 mg), and whether the effects persist or require dose escalation is unknown. No control comparison. The patient had sleeve gastrectomy specifically; effects may differ for other bariatric procedures.